Sbir phase I: respiratory dialysis for extracorporeal carbon dioxide treatment of copd

Ended Project Grant Awarded

Award ID
2415446
Recipient
Awarding agency
Obligated
$274,274

Award facts

Assistance listing
47.084 NSF Technology, Innovation, and Partnerships
Completion date
Place of performance
Washington, DC 20012, USA

Award details come from USAspending.gov.

Description

As the agency reported it.

Abstract
The broader impact of this small business innovation research (SBIR) phase I project is the development of a novel extracorporeal approach removing excess CO2 from the blood of chronic obstructive pulmonary disease (COPD) patients. COPD is a leading cause of death globally and is responsible for over 550,000 hospitalizations in the US annually at a total yearly cost of $50 billion. COPD leads to impaired quality of life, increased hospitalizations, and costs with poor overall prognosis despite modern interventions. Current end-stage treatments rely on mechanical ventilation, often resulting in further lung damage and high mortality rates. This project aims to develop an ultra-low-flow carbon dioxide removal system to support extubation, or avoid intubation, for providing respiration augmentation. The implementation of the therapy has the potential to reduce mechanical lung based interventions thereby improving patient outcomes, reducing adverse events associated with lung damage and diaphragmatic atrophy, and reducing overall hospitalization costs up to $17,000 per patient. This small business innovation research (SBIR) phase I project aims to optimize a prototype system providing respiratory dialysis to treat patients suffering from hypercapnic respiratory failure for extended durations. If successful, the project will address existing limitations of extracorporeal carbon dioxide removal techniques that requires high blood flow rates and specialized equipment. Results to date indicate significant increases in carbon dioxide capture efficiency versus existing methods, however risks and challenges remain in managing the removal of non-target ions and reducing dialysate waste generation. The specific objectives of this project are to develop a dialysate capable of capturing bicarbonate from the blood as a means of addressing hypercapnia while minimizing non-target and essential ions (K+, MG2+, CA2+). Additionally, this project aims to reduce the total dialysate usage requirement through a novel recirculation loop for dialysate recycling and reuse. If successful, the initiative will optimize dialysate composition and enable prolonged therapy while minimizing waste generation. This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the foundation's intellectual merit and broader impacts review criteria.- subawards are not planned for this award.

Quick answers

Who received award 2415446?

2415446 was awarded to X-Cor Therapeutics Inc. by National Science Foundation on August 7, 2024.

How much is award 2415446 worth?

$274,274 has been obligated on 2415446.

On GovTribe

See this award's full record

  • Every transaction and subaward
  • The recipient's other awards and teaming partners
  • Similar grant awards
  • Ask GovTribe AI about this award
Try for free Login